Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Son Long HoCenter for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-7175-246X
Xinrui MaDepartment of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-7970-3387
Colin M BashamCenter for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Weiling ZhaoDepartment of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Siyuan ChengDepartment of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Fangchao JiangDepartment of Chemistry, University of Georgia, 302 East Campus Road, Athens, Georgia 30602, United States.
Marina Sokolsky-PapkovCenter for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-3462-9013
Zhanhong WuDepartment of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Hong YuanDepartment of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jin XieDepartment of Chemistry, University of Georgia, 302 East Campus Road, Athens, Georgia 30602, United States.ORCID 0000-0002-8915-6233
Alexander KabanovCenter for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-3665-946X
Zibo LiDepartment of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-1063-0298
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
The development of novel radiation-sensitizer based on ultra-small carbon dotsR01CA247769 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, XIE, JIN · 2020 to 2024
$2.5M
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancerR01CA257851 · NCI · UNIVERSITY OF GEORGIA · PI KIM, WILLIAM Y., LI, ZIBO · 2021 to 2024
$2.1M
Development of IDO PET agents for immunotherapyR01CA233904 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, MOSCHOS, STERGIOS · 2019 to 2023
$2.0M
Small Animal PET/CT for Preclinical Imaging ResearchS10OD023611 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2017 to 2017
With the rapid development of the radiotheranostic field, developing new methods to produce radiolabeled agents has become a critical area of exploration. We hypothesized that the inert carbon shell of carbon dots (CDs) could serve as a robust chelation strategy to overcome the stability issue of radiometal complexes, including the recoil energy issue of alpha (α)-emitting radioisotopes. To investigate this, we utilized radioactive copper-64 (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Approach to Chelating Radioactivity using Carbon Dots for Positron Emission Tomography Imaging. · full record | OpenQuestion